

**Molecular and Cellular Mechanisms of Increased  
Angiogenesis in Multiple Myeloma:  
A Role for CXCL12**

**Sally K. Martin**

Myeloma Research Group  
Bone and Cancer Research Laboratory,  
Division of Haematology,  
Hanson Institute  
Institute of Medical and Veterinary Science

&

Department of Medicine,  
Faculty of Health Sciences  
University of Adelaide



A thesis submitted to the University of Adelaide  
for the degree of Doctor of Philosophy  
December 2008

# **TABLE OF CONTENTS**

<b>TABLE OF CONTENTS .....</b>	<b>i</b>
<b>DECLARATION .....</b>	<b>vi</b>
<b>ACKNOWLEDGEMENTS .....</b>	<b>vii</b>
<b>ABSTRACT .....</b>	<b>ix</b>
<b>ABBREVIATIONS .....</b>	<b>xi</b>
<b>LIST OF PUBLICATIONS .....</b>	<b>xv</b>
<b>1 INTRODUCTION .....</b>	<b>1</b>
1.1 An Overview .....	2
1.2 Multiple Myeloma .....	3
1.2.1 General Description .....	3
1.2.2 Epidemiology .....	3
1.2.3 Clinical Variants of Multiple Myeloma .....	4
1.2.4 Clinical Features of Multiple Myeloma .....	6
1.2.5 Treatment .....	7
1.3 Molecular Mechanisms of Physiological Angiogenesis .....	8
1.3.1 The Physiology of a Healthy Vascular System .....	8
1.3.2 Angiogenesis .....	9
1.3.3 The Angiogenic Switch .....	11
1.3.4 Angiogenesis in Cancer .....	11
1.3.5 Angiogenesis in Multiple Myeloma .....	12
1.4 The Chemokine System .....	14
1.4.1 The Role of Chemokines in Multiple Myeloma .....	16
1.4.2 CXCL12 and Its Receptor, CXCR4 .....	16
1.4.3 The Role of CXCL12 in Cancer .....	18
1.4.4 The Role of CXCL12 in Angiogenesis .....	19
1.4.5 The Role of CXCL12 in Multiple Myeloma .....	20
1.5 Hypoxia .....	21
1.5.1 The Hypoxia-Inducible Transcription Factors .....	21
1.5.2 Regulation of the HIF Transcription Factors .....	24
1.5.3 The Role of Hypoxia in Cancer .....	25
1.5.4 Hypoxia and Angiogenesis .....	26
1.5.5 The Hypoxia-Driven Regulation of CXCL12 and CXCR4 .....	27
1.6 Summary and Project Aims .....	28
<b>2 MATERIALS &amp; METHODS .....</b>	<b>29</b>
2.1 Suppliers of Commonly Used Reagents .....	30
2.2 Solutions, Buffers and Media for Cell Culture .....	31
2.2.1 Gelatin Solution .....	31
2.2.2 HUVEC Medium .....	31
2.2.3 TrHBMEC Medium .....	31
2.2.4 Roswell Park Memorial Institute Medium (RPMI-1640)-10 .....	31
2.2.5 Dulbecco's Modified Eagle's Medium (DMEM)-10 .....	32

2.2.6	HHF Wash Buffer .....	32
2.2.7	Blocking Buffer .....	32
2.2.8	Flow Cytometry Fixative (“FACS Fix”) .....	32
2.2.9	Standard Immunohistochemical Staining Solutions .....	32
2.2.9.1	Mayer’s Haematoxylin .....	32
2.2.9.2	Acid Alcohol (0.3% v/v).....	32
2.2.9.3	Scott’s Tap Water Substitute .....	32
2.3	Cell Culture Techniques .....	33
2.3.1	Maintenance of Cell Lines.....	33
2.3.1.1	Human Umbilical Vein Endothelial Cells (HUVECs).....	33
2.3.1.2	Transformed Human Bone Marrow Endothelial Cell Line (TrHBMEC)....	33
2.3.1.3	Human Myeloma Cell Lines.....	33
2.3.1.4	HEK-293T Packaging Cell Line.....	34
2.3.2	Cryopreservation of Cells .....	34
2.3.3	Thawing of Cryopreserved Samples.....	34
2.3.4	Collection of Conditioned Media .....	34
2.3.5	Cell Counts and Viability .....	35
2.3.6	<i>In vitro</i> Tube Formation Assays .....	35
2.3.7	Cytokines and Inhibitors Used in This Study .....	35
2.3.8	Cell Proliferation Assay (WST-1) .....	36
2.3.9	Immunofluorescent Staining and Flow Cytometric Analysis.....	36
2.3.9.1	Single Colour Immunofluorescence Staining.....	36
2.3.9.2	Primary Antibodies Used For Flow Cytometric Analysis in This Study ....	37
2.3.10	Immunohistochemical Staining .....	37
2.3.10.1	Bone Marrow Angiogenesis Analysis in Human Trephine Samples .....	37
2.3.10.2	Detection of CXCL12 in Sections of Bone Marrow Trephine .....	38
2.3.10.3	Detection of HIF-1 $\alpha$ and HIF-2 $\alpha$ in Sections of Bone Marrow Trephine .....	38
2.3.11	CXCL12 ELISA Immunoassay .....	39
2.4	<i>In vivo</i> Techniques .....	39
2.4.1	Mouse Strain and Animal Care.....	39
2.4.2	Intratibial Injection of Myeloma Cells.....	39
2.4.3	Subcutaneous Implantation of Alzet Osmotic Pumps .....	40
2.4.4	Subcutaneous Implantation of Myeloma Cells - Matrigel.....	40
2.4.5	<i>In vivo</i> Bioluminescence Scanning .....	40
2.4.6	Assessment of Haemoglobin Content in Murine Implants (Drabkin’s) .....	41
2.4.7	Analysis of Angiogenesis Data from Subcutaneous Implantation of MM PCs.....	41
2.5	Molecular Biology Buffers and Reagents.....	42
2.5.1	Diethyl pyrocarbonate (DEPC)-Treated (RNase-free) Milli-Q Water .....	42
2.5.2	Luria Broth (L-Broth) .....	42
2.5.3	LB Agar .....	42
2.5.4	5 x Acrylamide Load Buffer.....	42
2.5.5	2x Reducing Load Buffer .....	42
2.5.6	SDS “Running Buffer” for Electrophoresis.....	43
2.5.7	SDS-PAGE “Transfer Buffer” for Electrophoresis .....	43
2.5.8	1x TBE Buffer for Electromobility Shift Assays.....	43
2.6	Molecular Biology Techniques.....	43
2.6.1	Preparation of Total Cellular RNA.....	43
2.6.2	Determination of RNA Concentration and Purity .....	43

2.6.3	Synthesis of Complementary DNA (cDNA) .....	44
2.6.4	Real-Time Polymerase Chain Reaction (PCR).....	44
2.6.5	Primers Used in This Study .....	45
2.6.6	Preparation of Chemically Competent DH5 $\alpha$ Cells .....	45
2.6.7	Transformation of Competent Cells .....	46
2.6.8	Preparation of Glycerol Stocks .....	46
2.6.9	Purification of Plasmid DNA from Bacterial Cultures.....	46
2.6.9.1	Small Scale Plasmid DNA Extraction (Mini-Prep) .....	46
2.6.9.2	Medium Scale Plasmid DNA Extraction (Midi-Prep).....	46
2.6.10	Manipulation of DNA Products.....	46
2.6.10.1	Quantitation of DNA .....	46
2.6.10.2	Restriction Digestion of DNA .....	46
2.6.11	DNA Ligation .....	47
2.6.12	Sequencing.....	47
2.6.13	Preparation of Nuclear Extracts.....	47
2.6.14	RCDC Protein Estimation.....	47
2.6.15	Protein Detection -Western Immunoblot.....	48
2.6.15.1	Antibodies Used In This Study.....	49
2.6.16	Electrophoretic Mobility Shift Assay (EMSA) .....	49
2.6.16.1	Oligonucleotide and 32P-labelled Probe Preparation.....	49
2.6.16.2	Preparation of cellular extracts .....	50
2.6.16.3	EMSA analysis .....	50
2.6.17	Luciferase Reporter Assays .....	50
2.6.18	Chromatin Immunoprecipitation (ChIP).....	51
2.7	Retroviral Transfection and Infection Techniques .....	52
2.7.1	Cloning and Expression Vectors.....	52
2.7.2	Synthetic RNAi Knockdown Oligonucleotides for Retroviral Packaging .....	54
2.7.2.1	HIF-1 $\alpha$ and HIF-2 $\alpha$ RNAi .....	54
2.7.2.2	CXCL12 RNAi .....	54
2.7.3	Transfection of HEK-293T Packaging Cell Line with GFP-Encoding Plasmids .....	55
2.7.4	Viral Infection of Cells .....	55
2.7.5	Creation of Clonal Populations of Virally Infected Cells.....	56
2.8	Statistical Analysis.....	56

### **3 THE ROLE OF CXCL12 ON ANGIOGENESIS IN MULTIPLE MYELOMA .....**

<b>3.1</b>	<b>Introduction.....</b>	<b>58</b>
<b>3.2</b>	<b>Results.....</b>	<b>60</b>
3.2.1	Patient Studies.....	60
3.2.1.1	Bone marrow microvessel density is elevated in MM patients and correlates with plasma cell burden.....	60
3.2.1.2	Circulating levels of CXCL12 are elevated in MM patients and correlate with BM plasma cell burden and MVD.....	61
3.2.1.3	Circulating CXCL12 levels in MM and MGUS patients correlate with BM plasma cell burden and MVD.....	62
3.2.2	<i>In vitro</i> Studies.....	63
3.2.2.1	HUVECs and TrHBMECs express the CXCR4 receptor.....	63
3.2.2.2	The effect of recombinant human CXCL12 on <i>in vitro</i> tube formation.....	64

3.2.2.3	Myeloma cell line expression of CXCL12. ....	65
3.2.2.4	Inhibition of the CXCL12-CXCR4 pathway partially reduces myeloma-induced angiogenesis. ....	66
3.3	Summary and Discussion.....	68

## 4 THE ROLE OF HYPOXIA ON CXCL12 AND CXCR4

	<b>EXPRESSION: <i>IN VITRO</i> STUDIES .....</b>	<b>73</b>
4.1	Introduction.....	74
4.2	Results.....	77
4.2.1	Profiling of MM PC lines for hypoxic regulation of HIF-1 $\alpha$ and HIF-2 $\alpha$ and their target genes. ....	77
4.2.1.1	The hypoxic regulation of HIF-1 $\alpha$ protein expression in MM cell lines. ...	77
4.2.1.2	The hypoxic regulation of HIF-2 $\alpha$ protein expression in MM cell lines. ...	78
4.2.1.3	The downstream regulation of the HIF target genes: GLUT-1, CXCR4 and CXCL12. ....	78
4.2.2	Hypoxia up-regulates CXCR4 and CXCL12 protein expression in LP-1 cells. ....	80
4.2.3	Detailed characterisation of the cellular response to hypoxia in LP-1 cells. ....	81
4.2.3.1	The hypoxic regulation of GLUT-1, CXCR4 and CXCL12 mRNA expression in LP-1 cells. ....	81
4.2.3.2	The hypoxic regulation of HIF-1 $\alpha$ and HIF-2 $\alpha$ mRNA and protein..... expression in LP-1 cells. ....	82
4.2.4	The creation and characterisation of HIF-1 $\alpha$ - and HIF-2 $\alpha$ - over-expressing LP-1 cells. ....	83
4.2.4.1	The effect of HIF-1 $\alpha$ or HIF-2 $\alpha$ over-expression on CXCL12 and CXCR4 expression in LP-1 cells. ....	85
4.2.4.2	The effect of HIF-1 $\alpha$ or HIF-2 $\alpha$ over-expression on cell proliferation in LP-1 cells. ....	86
4.2.5	The creation and characterisation of HIF-1 $\alpha$ -knockdown in LP-1 cells. ....	86
4.2.5.1	The effect of HIF-1 $\alpha$ knockdown on GLUT-1, CXCR4 and CXCL12 mRNA expression in LP-1 cells. ....	88
4.2.5.2	The effect of HIF-1 $\alpha$ knockdown on CXCR4 and CXCL12 protein expression in LP-1 cells. ....	89
4.2.6	The creation and characterisation of HIF-2 $\alpha$ -knockdown in LP-1 cells. ....	90
4.2.6.1	The effect of HIF-2 $\alpha$ knockdown on GLUT-1, CXCR4 and CXCL12 mRNA expression in LP-1 cells. ....	91
4.2.6.2	The effect of HIF-2 $\alpha$ knockdown on CXCR4 and CXCL12 protein expression in LP-1 cells. ....	92
4.2.7	Detailed promoter analysis of the hypoxic induction of CXCL12 in LP-1 cells. ....	93
4.2.7.1	Luciferase reporter assays.....	93
4.2.7.2	HIF-2 $\alpha$ binds to the CXCL12 promoter. ....	94
4.3	Summary and Discussion.....	96

<b>5</b>	<b>THE ROLE OF CXCL12 AND HYPOXIA IN ANGIOGENESIS</b>	
	<i>IN VIVO</i> .....	<b>104</b>
5.1	Introduction.....	105
5.2	Results.....	107
5.2.1	Development and characterisation of a murine model to assess <i>in vivo</i> angiogenesis.....	107
5.2.1.1	Model 1: Intratibial injection of MM PCs and immunohistochemical assessment of angiogenesis.....	107
5.2.1.2	Model 2: Subcutaneous injection of MM PCs in Matrigel Matrix and immunohistochemical assessment of angiogenesis. ....	107
5.2.1.3	Drabkin’s assessment of haemoglobin content to measure angiogenesis..	108
5.2.1.4	The final model: Subcutaneous injection of MM PCs in Matrigel and Drabkin’s assessment of angiogenesis.....	109
5.2.2	The creation and characterisation of CXCL12 over-expression and CXCL12 knockdown in LP-1 cells.....	109
5.2.2.1	CXCL12 over-expression in LP-1 cells.....	109
5.2.2.2	CXCL12 knockdown in LP-1 cells.....	110
5.2.3	Characterisation of all engineered LP-1 cell lines created for this project....	111
5.2.3.1	CXCL12 and CXCR4 expression in all engineered LP-1 cell lines. ....	112
5.2.3.2	The proliferation rates of all engineered LP-1 cell lines. ....	112
5.2.4	<i>In vivo</i> studies .....	113
5.2.4.1	The role of CXCL12 in MM-induced angiogenesis.....	113
5.2.4.2	The role of HIF-1 $\alpha$ and HIF-2 $\alpha$ in MM-induced angiogenesis, and the contribution of CXCL12 to this process. ....	113
5.3	Summary and Discussion.....	115
<b>6</b>	<b>GENERAL DISCUSSION</b> .....	<b>120</b>
6.1	Summary & General Discussion.....	121
6.2	Therapeutic Implications of These Findings .....	123
6.2.1	Will anti-angiogenic therapies live up to expectation?.....	125
6.3	Future Directions .....	125
6.4	Perspectives and Concluding Remarks.....	127
<b>7</b>	<b>REFERENCES</b> .....	<b>128</b>
<b>8</b>	<b>APPENDICES</b> .....	<b>160</b>

## **DECLARATION**

This thesis contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968. The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

Signed

.....

Sally K. Martin

## **ACKNOWLEDGEMENTS**

So many people have helped me in so many ways throughout my PhD that to thank each person individually would take half a thesis in itself. So, to minimise the number of trees needed to print this thesis, I will try and keep this brief. However, it goes without saying that I deeply appreciate all of the help and support that I have received from everyone around me throughout my PhD.

First and foremost, I'd like to thank my supervisors A/Prof Andrew Zannettino, Dr Peter Diamond and A/Prof Stan Gronthos. Thank you for all the invaluable guidance, support and encouragement that each of you have given me along the way. I am one of the few PhD students lucky enough to have had supervisors who really care about me and go out of their way to make sure I'm doing alright. Without such great supervision, this task would have been infinitely more difficult and I wouldn't have learned nor accomplished so much. I really couldn't have hoped for better supervisors, and I am truly grateful for all that you have done for me.

I'd also like to thank my colleagues in the Bone and Cancer Research Laboratory, both past and present: Amanda Davis, Dr Andrea Dewar, Dr Stephen Fitter, Dr Sharon Hampton-Smith, Penny Kostakis, Kate Vandyke, Jenny Drew, Danijela Menicanin, Sharon Paton, Dr Agnes Arthur, Dr Peter Psaltis, Krzysztof Mrozik, Sandra Isenmann and Dr Naohisa Wada. You are all such fantastic friends and you've made it so easy to come to work every day. I really appreciate all of the help and encouragement that you have given me, and all of the moments of fun and laughter we've shared. I know that I can say this without any fear of contradiction - we have the best lab ever!

Many other people throughout the IMVS and Adelaide University have helped me over the years and also deserve a big thank you. Thank you to Dr Tony Cambareri for all of your help with the final editing of this thesis – without your assistance, I would still be battling with the numbering and tearing out my hair! Thank you to Kate Pilkington, for all of the many hours you have spent running my cells through the flow, for giving me lifts to work, organising Friday afternoon nibbles and for being a great friend. Thanks also to Jim Manavis for your invaluable immunohistochemical expertise, which was always given at a moment's notice, even though you're one of the busiest people I know. A big thank you to



Dr Agatha Labrinidis for all of your help with my animal studies, to Peter Self and the staff at Adelaide Microscopy for your assistance with my *in vivo* imaging studies, and to the IMVS animal house staff for taking care of my mice. Finally, thanks to Dr Dan Peet and Sam Olechnowicz for your guidance through the world of hypoxia and for providing reagents and advice whenever I needed it.

My friends and family have also given me endless support and encouragement, even though they were often neglected during the course of this PhD. Thank you for always asking how I was going, listening to me rambling on about what I've been doing, and making sure that I get the chance to relax. Thanks to Dad and my brother Greg, for your support. Thanks also to Gilia, Simon and Ruby, and to Ann, Tim, Kelly and Andy - I am very fortunate to have such a wonderful, supportive family. Thank you also mum who, even after all these years, I can still hear saying "slow down Sal... take your time... just make sure you do a good job". I have often felt you watching over me, and I know you'd be proud of what I have accomplished.

The biggest thank you of all goes to my husband Cameron for all of the encouragement and love that you have given me throughout these very challenging years. You more than any one has felt the highs and lows of this PhD, and never once have you let me down or failed to find some positive to pluck from a seemingly disastrous situation. Thanks for all the times that you came into work with me after hours, just to keep me company (even though you were tired and probably just wanted to go to sleep!). Thanks for always being there when I needed you, whether it was as a sounding board, to make me a cup of tea, or by keeping all your fingers crossed for me when I had a crucial experiment going. Your patience has been incredible, and I know I've sorely tested it at times! Without your love and support I would not have made it this far, and I will always be thankful to have you in my life.

And lastly, I would like to thank Professor Bik To for allowing me to undertake my studies in the Department of Haematology (and for offering me a good cleaning job when I finished my PhD!), and the University of Adelaide for providing financial support during my studies.

Thank you.

## **ABSTRACT**

Multiple myeloma (MM) is an incurable haematological malignancy characterised by the clonal proliferation of plasma cells (PCs) within the bone marrow (BM). MM PC survival and expansion is dependent upon an adequate supply of oxygen and nutrients, and increased BM angiogenesis is a critical feature of MM progression. While MM PCs express and secrete a number of angiogenic factors, our current understanding of the precise mechanisms by which MM-induced angiogenesis occurs is incomplete. In this study, we collected specimens from patients with MM and the benign precursor condition MGUS, and demonstrated for the first time that circulating levels of the CXCL12 chemokine positively correlate with the degree of BM angiogenesis. Using conditioned media from a MM PC line, the contribution of MM PC-derived CXCL12 to angiogenesis was also examined and found to strongly induce vascular tube formation *in vitro*.

In several other cell types, hypoxia has been shown to up-regulate CXCL12 expression. Studies investigating the hypoxic regulation of CXCL12 in MM PCs revealed that, while acute hypoxia is unable to stimulate CXCL12 expression, prolonged hypoxia significantly up-regulates CXCL12 mRNA and protein expression. To determine the mechanism(s) responsible for this, over-expression and RNA interference technology was employed to create genetically modified MM cells in which either HIF-1 $\alpha$  or HIF-2 $\alpha$  were over-expressed or knocked down. These studies showed that HIF-2 $\alpha$  is the predominant mediator of the hypoxic induction of CXCL12 in MM PCs. The ability of HIF-2 $\alpha$  to bind to the CXCL12 promoter was confirmed using EMSA and ChIP analyses.

The role of CXCL12 in *in vivo* angiogenesis and the contribution of HIF-1 $\alpha$  and HIF-2 $\alpha$  were also examined. In these studies, transduced MM cells, in which HIF-1 $\alpha$ , HIF-2 $\alpha$  and CXCL12 were over-expressed or knocked down, were implanted into a vessel-poor, subcutaneous environment in immunocompromised mice. Tumour-induced angiogenesis was assessed after two weeks by measuring the haemoglobin content of excised implants. These studies confirmed that over-expression of CXCL12, HIF-1 $\alpha$  and HIF-2 $\alpha$  each stimulates a strong angiogenic response. Using the well-characterised CXCR4 antagonist, T140, CXCL12 was found to play a key role in the increased angiogenesis observed in response to HIF-1 $\alpha$  and HIF-2 $\alpha$  over-expression.

These novel studies have shown that CXCL12 is an important mediator of angiogenesis in MM patients, and that aberrant CXCL12 expression by MM PCs is due, in part, to its hypoxic up-regulation mediated predominantly by HIF-2.

## ABBREVIATIONS

ALL	acute lymphoblastic leukaemia
AML	acute myeloid leukaemia
Ang	angiopoietin
ARNT	aryl hydrocarbon nuclear translocator
$\beta$ 2M	beta-2-microglobulin
bFGF	basic fibroblast growth factor
bp	base pairs
bHLH	basic helix-loop-helix
BM	bone marrow
BMSC	bone marrow stromal cell
BSA	bovine serum albumin
CAM	chorioallantoic membrane
cDNA	complementary deoxyribonucleic acid
CFU-En	colony forming units - endothelial
ChIP	chromatin immunoprecipitation
CLL	chronic lymphoblastic leukaemia
CM	conditioned media
CML	chronic myeloid leukaemia
CXCL	CXC chemokine ligand
CXCR	CXC chemokine receptor
DEPC	diethylpyrocarbonate
DMEM	Dulbecco's modified eagle medium
DMSO	dimethyl sulphoxide
DNA	deoxyribonucleic acid
EC	endothelial cell
ECM	extracellular matrix
EDTA	ethylenediaminetetra-acetic acid
eg.	for example
ELISA	enzyme-linked immunosorbent assay
EMSA	electromobility shift assay
ERK	extracellular signal-regulated kinase

FCS	foetal calf serum
Flk-1	foetal liver kinase-1 receptor
Flt-1	fms-like tyrosine kinase-1 receptor
GAPDH	glutaraldehyde 3-phosphate dehydrogenase
HBS	hypoxia inducible factor (HIF) binding site
HBSS	hank's balanced salt solution
HGF	hepatocyte growth factor
HIF	hypoxia inducible factor
hpf	high powered field of view
HRE	hypoxic response element
HUVEC	human umbilical vein endothelial cell
ID	inhibitory domain
ie.	that is
Ig	immunoglobulin
IGF	insulin-like growth factor
IL	interleukin
IRES	internal ribosome entry site
ISS	international staging system
i.u.	international units
kDa	kilodalton
LP-1-CXCL12	LP-1-pRUF-IRES-GFP-CXCL12
LP-1-CXCL12-KD	LP-1-pFIV-H1-copGFP-CXCL12 RNAi "Clone #8"
LP-1-HIF-1 $\alpha$	LP-1-pRUF-IRES-GFP-HIF-1 $\alpha$
LP-1-HIF-1 $\alpha$ -KD	LP-1-pFIV-H1-copGFP-HIF-1 $\alpha$ RNAi "Clone #4"
LP-1-HIF-2 $\alpha$	LP-1-pRUF-IRES-GFP-HIF-2 $\alpha$
LP-1-HIF-2 $\alpha$ -KD	LP-1-pFIV-H1-copGFP-HIF-2 $\alpha$ RNAi "Clone #2-6"
LP-1-pFIV	LP-1-pFIV-H1-copGFP
LP-1-pRUF	LP-1-pRUF-IRES-GFP
LP-1-scramRNAi	LP-1-pFIV-H1-copGFP-scrambled RNAi
LP-1-SFG	LP-1-SFG <sub>NES</sub> -TGL
M	molar
MDS	myelodysplastic syndrome
MFI	mean fluorescence intensity
MGUS	monoclonal gammopathy of undetermined significance

MIP	macrophage inflammatory protein
mg/ mL/ mm/ mM	milligram/ millilitre/ millimetre/ millimolar
MM	multiple myeloma
MMP	matrix metalloproteinase
MM PC	multiple myeloma plasma cell
M-protein	monoclonal paraprotein
mRNA	messenger ribonucleic acid
MVD	microvessel density
NHL	non-Hodgkin's lymphoma
nm	nanometres
OC	osteoclast
OD	optical density
ODD	oxygen-dependent degradation
PAS	Per-ARNT-Sim
PB	peripheral blood
PBS	phosphate buffered saline
PC	plasma cell
PCR	polymerase chain reaction
PDGF	platelet-derived growth factor
PE	phycoerythrin
pFIV	pFIV-H1-copGFP
PHD	prolyl hydroxylase domain
PI3K	phosphoinositide-3-kinase
pRUF	pRUF-IRES-GFP
RCC	renal cell carcinoma
rh	recombinant human
RNA	ribonucleic acid
RNAi	ribonucleic acid interference
RPMI	Roswell Park Memorial Institute
RT	room temperature
SDF-1	stromal-derived factor-1
SDS-PAGE	sodium dodecyl sulphate polyacrylamide gel electrophoresis
SEM	standard error of the mean
SMC	smooth muscle cell

TAD	transactivation domain
T140	4F-Benzoyl-TE14011 ( <i>in vitro</i> ) 4F-Benzoyl-TN14003 ( <i>in vivo</i> )
TGF	transforming growth factor
TNF	tumour necrosis factor
TrHBMEC	transformed human bone marrow endothelial cell
µg/ µl/ µm/ µM	microgram/ microlitre/ micrometre/ micromolar
VEGF	vascular endothelial growth factor
VHL	von Hippel Lindau
VLA	very late antigen
v/v	volume per volume
WST-1	4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulphonate
w/v	weight per volume
x g	times gravity

## LIST OF PUBLICATIONS

### Scientific Manuscripts

1. **SK Martin**, P Diamond, LB To, D Peet, S Gronthos and ACW Zannettino (2008). CXCL12 expression is regulated by HIF-2 $\alpha$  in multiple myeloma plasma cells. *Manuscript in Preparation.*
2. P Diamond, A Labrinidis, **SK Martin**, AN Farrugia, S Gronthos, LB To, N Fujii, P O'Loughlin, A Evdokiou and ACW Zannettino (2008). Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a xenogenic transplantation model of myeloma-associated bone loss. *Submitted to Journal of Bone and Mineral Research.*
3. A Labrinidis, P Diamond, **SK Martin**, S Hay, V Liapis, N Sims, GJ Atkins, T Vincent, DM Findlay, ACW Zannettino and A Evdokiou (2008). Apo2L/TRAIL inhibits tumour progression and bone destruction in a murine model of multiple myeloma. *Submitted to Clinical Cancer Research.*
4. A Labrinidis, P Diamond, **SK Martin**, S Hay, V Liapis, DM Findlay, ACW Zannettino and A Evdokiou (2008). Multimodal imaging analysis of tumour progression and bone destruction in a murine model of multiple myeloma. *Submitted to International Journal of Oncology.*
5. ACW Zannettino, **SK Martin**, S Gronthos, LB To and DJ Peet (2008). The role of CXCL12 in multiple myeloma. *Cancer Research Progress*. Nova Publishers. Edited by Henrik N. Kristiansen.
6. **SK Martin**, AL Dewar, AN Farrugia, N Horvath, S Gronthos, LB To and ACW Zannettino (2006). Tumour angiogenesis is associated with plasma levels of stromal-derived factor-1 $\alpha$  in patients with multiple myeloma. *Clinical Cancer Research*, 12(23): 6973-6977.



7. ACW Zannettino, AN Farrugia, A Kortesis, J Manavis, LB To, **SK Martin**, P Diamond, H Tamamura, T Lapidot, N Fujii and S Gronthos (2005). Elevated serum levels of stromal-derived factor-1 $\alpha$  are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. *Cancer Research*, 65(5): 1700-1709.
8. **SK Martin**, LB To and ACW Zannettino (2004). Angiogenesis in multiple myeloma: Implications in myeloma therapy. *Cancer Reviews: Asia-Pacific*, 2(2): 119-129.

### **Conference Proceedings: Poster Presentations**

1. 30<sup>th</sup> Annual Meeting of the American Society for Bone and Mineral Research, Montreal, Canada, September 2008. *CXCL12 Expression is Regulated by HIF-2 $\alpha$  in Multiple Myeloma Plasma Cells*. **SK Martin**, P Diamond, LB To, D Peet, S Gronthos and ACW Zannettino.
2. 30<sup>th</sup> Annual Meeting of the American Society for Bone and Mineral Research, Montreal, Canada, September 2008. *CXCL12 Stimulates Osteoclastic Bone Resorption in a Novel Mouse Model of Human Multiple Myeloma*. P Diamond, A Labrinidis, **SK Martin**, AN Farrugia, S Gronthos, LB To, A Evdokiou and ACW Zannettino
3. 2<sup>nd</sup> International Conference on Osteoimmunology: Interactions of the Immune and Skeletal Systems, Rhodes, Greece, June 2008. *The Role of the Chemokine CXCL12 in Induction of Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma*. P Diamond, S Hampton-Smith, A Labrinidis, **SK Martin**, S Gronthos, LB To, N Fujii, P O'Loughlin, A Evdokiou and ACW Zannettino.
4. 11<sup>th</sup> International Myeloma Workshop, Kos, Greece, June 2007. *CXCL12 Stimulates Osteoclastic Bone Resorption in a Novel Mouse Model of Human Multiple Myeloma*. P Diamond, A Labrinidis, **SK Martin**, AN Farrugia, S Gronthos, LB To, A Evdokiou and ACW Zannettino.

5. 11<sup>th</sup> International Myeloma Workshop, Kos, Greece, June 2007. *Tumour Angiogenesis is Associated with Plasma Levels of Stromal-Derived Factor-1 $\alpha$  in Patients with Multiple Myeloma.* **SK Martin**, AL Dewar, AN Farrugia, N Horvath, S Gronthos, LB To and ACW Zannettino.
  
6. 10<sup>th</sup> International Myeloma Workshop, Sydney, Australia, April 2005. *Myeloma Plasma Cell-Derived SDF-1 $\alpha$  and RANKL act Synergistically to Stimulate Neo-Angiogenesis.* **SK Martin**, AN Farrugia, P Diamond, LB To and ACW Zannettino.
  
7. 10<sup>th</sup> International Myeloma Workshop, Sydney, Australia, April 2005. *Elevated Serum Levels of CXCL12 is Associated with Increased Osteoclast Activity and Osteolytic Bone Disease in Multiple Myeloma Patients.* AN Farrugia, S Gronthos, A Kortesisidis, J Manavis, LB To, **SK Martin**, P Diamond, H Tamamura, T Lapidot, N Fujii and ACW Zannettino.